Marshall Fordyce - 16 Nov 2022 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Role
President and CEO, Director
Signature
/s/ Joseph R. Young, Attorney-in-Fact
Issuer symbol
VERA
Transactions as of
16 Nov 2022
Net transactions value
+$185,750
Form type
4
Filing time
17 Nov 2022, 15:06:10 UTC
Previous filing
05 Oct 2022
Next filing
17 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERA Class A Common Stock Options Exercise $11,942 +5,153 +2.8% $2.32* 186,303 16 Nov 2022 Direct
transaction VERA Class A Common Stock Options Exercise $173,808 +60,000 +32% $2.90* 246,303 16 Nov 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -5,153 -91% $0.000000 516 16 Nov 2022 Class A Common Stock 5,153 $2.32 Direct F1
transaction VERA Stock Option (Right to Buy) Options Exercise $0 -60,000 -6.3% $0.000000 887,212 16 Nov 2022 Class A Common Stock 60,000 $2.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3 of the shares subject to the option vested on January 10, 2021, and 1/36 of the shares vest monthly thereafter.
F2 1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.